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This report describes the clinical results of using
controlled collagen-denaturation contraction to
reduce vein luminal diameters in specific ways to
eliminate or markedly diminish saphenous vein
reflux. Vein wall collagen denaturation was induced
by endovenous application of radiofrequency-resis-
tive heating, which is not itself a novel therapy.
Seven articles, published between 1964 and 1994,
have portrayed clinical efforts to destroy truncal or
tributary varicosities by endovenous electrosurgical
dessication.1-7 The therapies to be described here
differ markedly from the foregoing in that their
intent is not vein destruction but rather precise heat-
ing, feedback controlled by vein wall temperature
and impedance, and sufficient to cause the necessary
collagen contraction without destroying vein wall
integrity.
The molecular contractile forces that attend col-
lagen denaturation were identified more than 80
years ago, and the underlying transformation of the
native helix to random coils, which can contract a
collagen molecule to as little as one fifth of its origi-
nal length, was characterized 40 years ago.8 Clinical
application of these forces to a variety of disease con-
ditions characterized by dilatation and laxity has been
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repeatedly frustrated by difficulties in process con-
trol, variations in circulatory heat dissipation, early
contraction-relaxation that occurs with partial renat-
uration, and tensile weakness during healing.9-12 In
the present instance, thermal effects are confined
through use of bipolar electrodes, which concentrate
current density along minimal impedance paths
between the poles,13 and by excluding blood flow
from the treatment area during energy application.
The devices are catheter-based and sized to accom-
modate the expected range of vessel diameters. Two
basic designs permit either drawback heating along
an entire vein segment for complete lumen closure
(Fig 1) or limited constriction (Fig 2) of a short vein
wall segment immediately beneath an incompetent
valve with mobile but nonocclusive leaflets to narrow
its annulus and restore leaflet approximation. The
obliterative treatment minimizes wall relaxation by
leaving behind a small thrombus plug in the 
contracted, de-endothelialized lumen (Fig 1, B),
effectively isolating the closed segment from internal
hydrostatic pressure, whereas the restorative 
procedure deals with this problem by slight initial
overshrinking and posttreatment measures to aug-
ment deep venous flow, such as knee-length support
hose, programmed walking, and avoidance of 
prolonged sitting and standing. 
MATERIALS AND METHODS
The system. The treatment system comprises 
a dedicated low-wattage, computer-controlled,
radiofrequency generator and two sizes each of
Closure and Restore catheters (VNUS Medical
Technologies, Inc, Sunnyvale, Calif). Each catheter
has a central lumen for fluid infusion and the option
of passage over a guide wire. The 1.7-mm (5 Fr) and
2.7-mm (8 Fr) Closure catheters differ slightly in
design (Fig 3, A), electric polarity being exchanged
between a ball-tipped central element and a single
tuft of collapsible electrodes in the smaller catheter
and between two tufts of collapsible electrodes (with
a neutral central element) in the larger catheter.
Together, the two catheters can treat veins with
diameters ranging from 2 to 12 mm. The two
Restore catheter sizes (2.7 mm [8 Fr] and 3.0 mm
[9 Fr]) share the electrode configuration shown in
Fig 3, B; together, they are applicable to valve diam-
eters from 4 to 15 mm. The contractile forces are
such that the Restore electrodes need to have con-
siderable resilience to resist uncontrolled shrinkage.
Each catheter has a microthermocouple to monitor
vein wall temperature once good wall contact has
been achieved. Good wall contact is defined by a
sudden increase in impedance over that displayed
Fig 1. Hematoxylin and eosin–stained cross sections of lateral saphenous veins, taken at mid thigh from
similarly sized goats (all at 10× original magnification). A, Untreated. B, Closed by thermal collagen-
denaturation contraction, seen at 3 days. C, Closed by thermal collagen-denaturation contraction, seen at
6 weeks. Note 60% contraction and vein wall thickness doubling with glassy hyalinization at 3 days, and
note thrombus maturation with fibrosis and vaso vasorum ingrowth at 6 weeks.
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when the electrodes are surrounded by blood. The
generator provides a separate low-current impulse
circuit for impedance testing, identifies the catheter
model attached to it, and automatically selects its
appropriate feedback algorithm. 
The Closure procedure. Closure treatment is
applicable to any refluxing superficial or perforator
vein that is not too tortuous for catheter passage, and
it can be used as a stand-alone treatment or integrat-
ed with other therapies. The Closure catheters
ensheathe the collapsible electrodes, presenting a
ball-tipped central element for prograde introduction
by ultrasound-guided percutaneous puncture, as was
done in approximately 15% of the study limbs, or
through a small distal incision, as was done in
approximately 65% of the study limbs. They can also
be passed retrograde from an open groin wound, as
was done in approximately 20% of the study limbs,
when ligation of the saphenofemoral junction and its
tributaries is to be part of the procedure. Prograde
advancement to the long or short saphenous vein
junctions with the common femoral or popliteal
veins can be guided by ultrasonic visualization during
the procedure, which is preferable, or by preliminary
duplex scan imaging and skin marking. When the
catheter is in position, the limb is elevated, and an
Esmark elastic bandage is wrapped from the base of
the toes to the groin or to well above the knee if the
treatment is to be confined to the leg. The purposes
of the wrap and elevation are to exclude blood flow
from the entire superficial venous network and to
facilitate return through the deep system. Direct
manual compression is needed over the groin.
Heparinized saline solution is infused through the
catheter’s central lumen to avoid coagulum accumu-
lation on the electrodes. Once the treatment circuit
is activated and the therapeutic temperature of 85°C
is achieved, the catheter is to be withdrawn at 2.5 to
3.0 cm/min, a wall temperature within 3°C of the
therapeutic value always being maintained. In prac-
tice, the mean pullback rate has varied considerably;
the median rate was 3.5 cm/min.
The Restore procedure. The Restore treatment
is only applicable to a refluxing valve with mobile
leaflets that can be demonstrated by duplex ultra-
sound scanning to become competent when its
diameter is reduced by external compression to a
definable size (“the competence diameter”), at
which the leaflets approximate and reflux is abol-
ished or markedly diminished. High-resolution
ultrasonic imaging is needed during the procedure
for proper electrode placement, because the central
active area of the electrodes must be within less than
1 cm of the valve base and yet not impinge on the
leaflets. Because limited intimal injury is inherent in
the procedure, prophylactic low-molecular-weight
heparin is given before the procedure and for 6 days
afterward, and an infusion of unfractionated heparin
is started immediately after insertion of the intro-
ducer sheath and continued throughout the proce-
dure. Blood flow is excluded from the treatment
area by base-of-toes-to-groin Esmark wrapping and
supplemental manual compression of the groin trib-
utaries. The electrodes are expanded to make good
wall contact, defined by impedance testing, and acti-
vated. Once the therapeutic temperature of 72°C is
Fig 2. Masson trichrome–stained cross sections of lateral saphenous veins contracted to predetermined
diameter (both sections were taken at mid thigh from similarly sized sheep and photographed at 10× orig-
inal magnification). A, Seen at 3 days. B, Seen at 3 weeks. Note apparent wall relaxation at 3 weeks.
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established, the electrodes are progressively closed,
at a rate guided by maintenance of wall contact
impedance, to the treatment “target diameter,”
which is 1 mm less than the predetermined compe-
tence diameter, with a lower limit of 4 mm.
Typically, 2 minutes of energy application are
required, including a final 15 seconds at the target
diameter.
Patients and treatment centers. Each of 210
patients (154 women and 56 men) with a mean (±
SD) age of 45 ± 13 years was treated with either
Closure or Restore catheters at one of 16 European
private clinic and university vascular and phlebology
services. Women were slightly more predominant
among the 142 Closure patients (106:36) than they
were in the group of 68 patients treated with
Restore (48:20; P = .534). Each patient had demon-
strable saphenous vein reflux, as determined either
by duplex ultrasound scanning during a Valsalva
maneuver with the patient in 15-degree reverse
Trendelenburg or by calf compression-release with
the patient standing. Patient positioning and the
maneuver to provoke reflux were the same for every
examination at a given study site. Patients with post-
thrombotic deep-system changes or dominant deep-
system incompetence were excluded. The combined
patient group represented the range of venous reflux
disease, including active ulceration; the mean
Clinical Efficacy Assessment Project (CEAP) clinical
class was 2.5 ± 0.9.14 Closure and Restore patients
had similar disease severity spectrums: 95% had
symptomatic primary varicosities, 1 Closure and 3
Restore patients were class 5, and 1 Closure patient
had an active ulcer. Clinical follow-up visits with
duplex scanning of the entire Closure-treated vein,
measurements of Restore-treated valve diameter and
function, and scanning of the relevant deep-vein
junction were programmed for within 1 week of
treatment, at 6 weeks, and at 6 and 12 months. In
addition, notations were made at each visit of symp-
toms, new or recurrent varicosities, CEAP clinical
class, and any new or ongoing complications.
Nine sites were involved in Closure treatment
only, three restricted their activities to Restore annu-
lus shrinking, and four were involved in both study
treatments. Patients at these last four centers were
selected for Restore treatment if they were identified
to have a demonstrable restorable valve and did not
express preference for Closure treatment. The two
treatments were not used together in any patient. 
Statistical analysis. The Fisher exact test or the
χ2 test was used to compare proportions. Paired
observations of continuous and ordinal data were
evaluated through use of the Wilcoxon signed rank
test, and, for multiple groups, analysis of variance.15
When potentially confounding covariables were pre-
sent, analysis of covariance was used.15
RESULTS
Closure treatment
Acute results. Table I presents the acute results
of treating 152 veins in 151 lower limbs in 142
patients. Twenty percent of the treatments were
done with patients under general anesthesia, 50%
with patients under conduction anesthesia, and 30%
with local infiltration or tumescent infiltration.
Closure treatment acutely abolished reflux and
duplex-detectable flow in 141 limbs (93%); this was
defined as no flow more than 5 cm below the saphe-
nofemoral junction at the conclusion of treatment
and through the first week of follow-up. Two fail-
Fig 3. A, Closure catheters (note cupped, uninsulated
electrode tips). B, Restore catheter (note central 9-mm
uninsulated electrode areas). Arrows indicate microther-
mocouples.
Fig 4. Symptom prevalence (%) in 53 Closure patients fol-
lowed up for 6 months or more.
A B
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Table I. Closure acute treatment results
Adjunctive prior or 
concurrent procedure Complication
No. Acute High Stab wound
Vein segment treated occlusion ligation phlebectomy SP P TSI TE
Above-knee long saphenous 104* 97 34 84 11 9 2 3
Below-knee long saphenous 4 4 2 3 1 2 — —
Entire long saphenous 39 35 22 21 3 19 1 —
Short saphenous 4 4 2 3 — 3 — —
Accessory saphenous 1 1 0 1 — — — —
Totals (%) 152 (100) 141 (93) 60 (40†) 112 (74†) One or more: 47 (31†)
*Includes one accessory saphenous vein treated in conjunction with an above-knee long saphenous vein.
†Percent based on 151 treated limbs (in 142 patients).
P, Paresthesia; SP, symptomatic phlebitis; TE, thrombus extension; TSI, thermal skin injury.
ures that involved above-knee long saphenous veins
in patients having concomitant high ligations were
immediately remediated by surgical stripping. An
additional failure involved only the below-knee seg-
ment of an entire long saphenous vein treatment;
the below-knee segment was stripped and the above-
knee portion remained occluded at 1 year. The
remaining seven acute failures were not apparent at
the time of treatment but became evident within the
first week. 
Complications. Closure treatment complications
were primarily related to thermal energy dissemina-
tion beyond the vein wall, and, in three instances, to
deep-vein thrombus propagation. Histologic
phlebitis was expected as part of the Closure obliter-
ative and repair process, but 15 veins developed ten-
derness and induration over the course of the treated
segment (indicated as “symptomatic phlebitis” in
Table I). Eight of these patients were treated before
base-of-toes-to-groin Esmark wrapping and head-
down positioning were routinely used to minimize
residual lumen thrombus, but almost as many
instances occurred after these techniques were adopt-
ed. These latter injuries usually did not become
apparent until 1 to 3 weeks after treatment and were
indicative of thermal damage to tissues surrounding
the vein, including the deeper portion of the dermis.
At the other end of the spectrum, three patients had
full-thickness thermal skin injuries; all three were
men with visibly very superficial veins. These were, of
course, inside-out burns, with sufficient thermal pen-
etration to damage the germinative layer of the epi-
dermis. They were also not immediately apparent and
took 1 to 3 weeks to evolve. One full-thickness injury
healed with simple topical therapy, but the other two
required systemic antibiotics, one of these also need-
ing dependent surgical drainage of a subcutaneous
abscess 6 weeks after treatment.
Paresthesia, defined as numbness or dysesthesia
persisting for at least 6 weeks and taken to be indica-
tive of thermal damage to femoral cutaneous nerve
branches, developed after nine (9%) of 104 Closure
treatments limited to the thigh and immediately
below the knee; in contrast, 21 (49%) of 43 treat-
ments involving the below-knee long saphenous
vein to the ankle and three (75%) of four treatments
involving short saphenous vein caused saphenous or
sural nerve paresthesias (P < .001). Sixteen patients
with paresthesia progressed to the 6-month follow-
up, and 13 still reported localized numbness or tin-
gling, only one of these being a patient with thigh
paresthesia. Five patients have reached the 1-year
mark, with three having persistent saphenous or
sural nerve paresthesias. 
Three of 86 limbs in which the above-knee long
saphenous vein was treated without high ligation
developed thrombus extensions into the common
femoral vein. One of these patients, who was treated
without intraprocedural duplex scanning imaging,
incurred a deltoid ligament sprain from a fall in the
operating suite dressing room that caused her to
spend most of her days sitting and thus not to com-
ply with the prescribed walking program. She
returned for her 1-week follow-up visit with dyspnea
but with no leg symptoms other than ankle pain.
Duplex scanning imaging showed a floating throm-
bus extending from the orifice of the long saphenous
vein, as well as thrombi in the treated-limb peroneal
and posterior tibial veins. A spiral computerized
tomographic scan confirmed the presence of several
pulmonary emboli. Her symptoms and thrombus
extension resolved on treatment with heparin, which
was followed by long-term Coumadin therapy. The
other thrombus extensions were clinically silent and
recognized on routine duplex scanning at 3 and 5
days after treatment. Both completely resolved dur-
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ing the first 4 days of a 1-week program of low-mol-
ecular-weight heparin treatment.
Midterm results. Fourteen (10%) of the suc-
cessfully treated veins developed Doppler scanning
evidence of flow: 8 by 6 weeks, 4 by 3 months, and
2 by 6 months. These were clearly failures on an
intent-to-treat basis inasmuch as permanent obliter-
ation was not achieved, but Doppler-identifiable
reflux was observed in just eight of the 14 reopened
segments. Only one recanalization involved the
entire treatment length. The rest were of limited
extent and asymptomatic, except for one reopening
of a 5-cm segment of an above-knee saphenous vein
treatment at 6 months that was associated with the
new appearance of a varicose, incompetent, Dodd’s
perforating vein. When seen at 1 year, the segment
had reclosed despite the continued presence of the
incompetent perforator. Recurrent or new varicosi-
ties followed the single complete recanalization and
also appeared in four limbs with obliterated veins,
giving Closure treatment, at a mean follow-up of 4.7
months, a 6% recurrent reflux rate and a 4% inci-
dence of recurrent varicosities.
Fifty-three Closure patients (55 limbs) have pro-
gressed to the 6-month follow-up, and 19 (20 limbs)
have reached 1 year. Ninety-one percent had persis-
tent occlusion at 6 months, with reflux in just two of
the five reopened segments. All 1-year–follow-up
veins were occluded. The CEAP clinical class distri-
butions before treatment and at the 6-week, 6-
month, and 1-year follow-up visits are shown in
Table II, along with comparable data for Restore
patients. Eighty-seven percent of Closure patients
were class 0 or class 1 at 6 months, as were 18 of 19
at 1 year. Thirty-nine patients had saphenofemoral
junction ligation: their mean class improvement at 6
months of –1.4 ± 1.2 was less than the –2.4 ± 1.5 of
the 14 no-high-ligation patients, but this became
nonsignificant when the covariance of the no-high-
ligation group’s higher mean pretreatment class (2.8
vs 2.2) was entered into the analysis (P = .352). The
decreased prevalence of individual symptoms, shown
in Fig 4, was sustained through 1 year except in 3
patients, 1 with new edema at 6 months, 1 with
recurrent edema at 12 months, and 1 with a new
varicosity at 12 months. At 6 months, 40 patients
Table II. CEAP clinical class before and after treatment for patients followed up for ≥ 6 months
Closure (n = 33 at 6 mo; n = 19 at 12 mo) Restore (n = 31 at 6 mo; n = 17 at 12 mo)
Class* Pretreatment 6 wk 6 mo 12 mo Pretreatment 3/6 wk 6 mo 12 mo
0 1 27 31 9 0 15 9 8
1 1 12 15 9 0 2 5 2
2 38 6 4 1 20 10 14 7
3 7 3 1 0 7 2 1 0
4 5 3 1 0 3 1 1 0
5 1 1 1 0 1 1 1 0
6 0 1 0 0 0 0 0 0
Mean ± SD 2.3 ± 0.8 1.1 ± 1.5† 0.7 ± 1.1† 0.6 ± 0.6† 2.5 ± 0.8 1.2 ± 1.4† 1.4 ± 1.2† 0.9 ± 1.0†
*Clinical classification: 0, no visible or palpable signs of venous disease; 1, telangiectasias, reticular veins, or malleolar flare; 2, varicose
veins; 3, edema without skin changes; 4, skin changes ascribed to venous disease (pigmentation, venous eczema, or lipodermatosclero-
sis); 5, skin changes with healed ulceration; 6, skin changes with active ulceration.14 In instances of bilateral treatment, class determina-
tion was based on more affected limb.
†P = .0001 vs pretreatment.
Table III. Restore acute treatment results
Competence  Adjunctive stab Complication
Valves No. of diameter Reflux Reflux wound 
treated patients achieved ≤ 0.5 s < 1 s phlebectomy OT SP P Total
Terminal alone 24 20 12 15 7 1 1 — 2
Subterminal alone 24 22 13 13 13 5 1 — 6
Terminal and subterminal 15 10 10 10 5 4† — 2 6
Other* 5 3 2 3 2 1 — — 6
Totals (%) 68 (100) 55 (81) 37 (54) 41 (60) 27 (40) 11 (16) 2 (3) 2 (3) 15 (22)
*Indicates treatment of more distal valve in combination with a terminal or subterminal valve (three instances) or with both (two
instances).
†Includes one thrombus that extended into common femoral vein.
OT, Occlusive thrombosis; SP, symptomatic phlebitis; P, paresthesia.
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(75%) were completely free of venous disease–related
symptoms, in part, perhaps, because of adjunctive
phlebectomies in 34 instances. The six symptom-free
patients who did not have avulsion phlebectomies
were six (86%) of the seven patients treated without
adjunctive phlebectomy who had reached 6 months
of follow-up.
Restore treatment
Acute results. Table III shows the valves that
were treated and the acute treatment results. No
patient had bilateral treatments. Forty percent of the
procedures were done with the patients under gen-
eral anesthesia. In 50%, conduction anesthesia was
used, and 10% were done with local infiltration. All
valves were in the long saphenous vein, between the
saphenofemoral junction and the mid thigh.
Treatments involved a single valve in 48 patients
(80%), 2 valves in 18 patients, and 3 valves in 2
patients. Early in the study, more than one valve was
often treated in the belief that the more proximal
valve, or valves, would protect a distal valve from
hydrostatic pressure during healing. Later, concern
about early thrombosis tempered enthusiasm for
causing multiple intimal injuries, but in two
instances second valves were treated because the
investigator could not achieve satisfactory reflux
reduction with the first valve. The 20 limbs with
more than one treated valve were scored on a “best-
case valve” basis to avoid an overly fragmented
analysis of 1-valve, 2-valve and 3-valve cases, since a
single competent valve was expected to be a con-
trolling feature. Best-case valve selections were based
on reflux duration measurements of each treated
valve at the 3-week or 6-week follow-up visit, the
valve with the best competence being designated the
controlling valve. Once the selection was made, it
was never changed. The selected valve’s baseline and
1-week diameters and reflux data were retrospective-
ly designated to represent these earlier time points,
and all subsequent follow-up data were taken from
the same valve. The mean acute valve diameter
reduction for all 68 limbs was 7.5 ± 1.6 mm to 4.5
± 1.4 mm (37 ± 20%; P <.0001). Competence diam-
eters were achieved for at least one valve in 81% of
patients, but the goal of acutely diminishing reflux
to less than 1 second16 was accomplished in only 41
limbs (60%), even though the mean reflux duration
reduction was 81%.
Complications. Symptomatic phlebitis and
paresthesia were uncommon, as shown in Table III,
but the incidence of early occlusive thrombosis was
16% despite routine unfractionated heparin infusion
during treatment and a week of low-molecular-
weight heparin prophylaxis. Six of the 11 throm-
boses were clinically silent, but all were identifiable
by duplex scanning imaging within 7 days of treat-
ment. The thromboses typically occluded the proxi-
mal two thirds of the thigh portion of the saphenous
vein. One thrombus propagated into the common
femoral vein, which was treated by open thrombec-
tomy followed by ligation of the junctional tribu-
taries and stripping of the above-knee long saphe-
nous vein. Nine of the remaining 10 thromboses
were followed for 6 weeks or more: five of these
veins remained occluded, and four were patent with
more than 1-second recurrent reflux.
Midterm results. Fig 5 shows the valve diame-
Fig 6. Box-and-whisker plots of reflux duration for 31
Restore patients followed up for 6 months or more (P val-
ues vs pretreatment reflux duration).
Fig 5. Box-and-whisker plots of valve diameters of 31
Restore patients followed up for 6 months or more (P val-
ues vs pretreatment diameter).
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ters for 31 Restore patients without thrombotic
occlusion who were followed up for 6 months or
more; 17 of these patients were followed up to 1
year. The diameters tended to reexpand between
week 1 and week 3 or week 6 despite uniform com-
pliance with respect to the wearing of below-knee
compressive hose and programmed walking. Valve
diameters were stable thereafter and significantly dif-
ferent from baseline values through 6 months. Fig 6
shows deterioration in valve competence during the
first 6 months but with significantly less reflux than
before treatment out to 1 year. Six-month changes in
valve diameter for the 14 limbs with two or more
treated valves and reflux were not different from
those for the 17 limbs with only one treated valve 
(P > .336). Significant clinical class improvement was
sustained through 1 year, but 55% of the patients
were class 2 or higher at 6 months (Table II).
Individual symptoms began to reappear by 6 months
(Fig 7); four patients experienced return of pain or
fatigue associated with new varicosities, and three
additional patients developed pain or fatigue by 1
year. Fourteen patients (45%) remained asymp-
tomatic at 6 months, in part because of adjunctive
phlebectomies in 11 instances; however, as shown in
Fig 8, only 6 patients had reflux at less than 1 second,
and just one patient had a valve diameter substantial-
ly smaller than it was originally.
Effect of variable treatment site activity. The
two most active sites treated 30 patients each (one
doing only Closure treatment and one offering both
treatments). Of the two least active study sites, one
treated three Closure patients, and the other treated
three Restore patients. The possible bias of poorer
results in the less active centers was tested by com-
paring the proportions of acute treatment failures
and complications for each treatment independently
at centers treating 10 patients or more versus those
at sites treating less than 10 patients. As shown in
Table IV, significant differences were not observed,
due consideration being given to the low power of
small sample sizes.
DISCUSSION
The endovenous treatment results described in
this report illustrate the clinical benefit that can
accrue from harnessing collagen denaturation forces,
but they also speak to the vexing issues of process
control that must be surmounted in transiting from
the laboratory to practical clinical therapy. Rat tail
Fig 7. Symptom prevalence (%) in 31 Restore patients fol-
lowed up for 6 months or more.
Fig 8. Reflux and symptom absence as functions of valve
diameter change at 6 months (circles; n = 14) and 12
months (triangles; n = 17); black symbols indicate symp-
tom-free patients.
Table IV. Acute treatment failure and complications by treatment site activity
Treatment Events Sites treating 3 to 9 limbs Sites treating 10 to 30 limbs P* value
Closure
Acute failure (%) 2/25 (8) 8/126 (6) .671
Complications (%) 7/25 (28) 47/126 (37) .645
Restore
Acute failure (%) 4/7 (57) 23/61 (38) .423
Complications (%) 3/7 (43) 12/61 (20) .175
*Two-tailed Fisher exact test.
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tendon collagen in aqueous solution and chordae
tendineae in water baths contract in a predictable
manner in response to temperatures varying from
65° to 90°C, requiring more time at lower tempera-
tures to achieve equivalent contraction.8,12 The
Restore treatment operates toward the lower end of
this range (72°C) to maximize contraction control
and limit the endothelial lesion. Closure treatment is
done in the higher range (85°C) to ensure maximal
contraction and shorten the time required for a ther-
apeutic effect so that catheter withdrawal can pro-
ceed at a reasonable pace.
Closure treatment
The midterm results of Closure treatment were
quite promising, encompassing significant improve-
ment in CEAP clinical class and 75% freedom from
all venous disease–related symptoms in 55 limbs at 6
months. These results reflect Closure treatment with
and without high ligation and adjunctive avulsion
phlebectomies. The results with and without high
ligation were equivalent. Avulsion phlebectomies are
appropriate with Closure treatment, just as they are
with saphenous stripping, when established varicose
saphenous tributaries or clusters associated with
incompetent perforating veins are present.
Closure-treated veins that remained occluded at
6 weeks had a small likelihood (6%) of having even a
short patent segment at subsequent follow-ups, and
one short segment that opened from the pressure of
an incompetent perforating vein spontaneously
reclosed despite persistence of the varicose perfora-
tor. The Closure catheters and generator algorithms
evolved with thermal effect confinement as a major
design constraint. Investigators in the 1960s and
1970s, reporting on 68 saphenous vein treatments
in 48 patients in one instance and 389 patients (fol-
lowed for up to 7 years) in the other, had observed
third-degree skin burns, particularly in male
patients, and noted an incidence of saphenous nerve
injuries of approximately 20%.2,3 Low-wattage,
bipolar current, and specific electrode designs, cou-
pled with control algorithms governed by frequent
wall temperature and impedance sampling, were
expected to avoid thermal damage to adjacent tis-
sues, but our experience to date has shown that four
procedural constraints are also needed to minimize
complications and early failures.
The first procedure modification is directed at
avoiding thermal skin injury. When the vein to be
treated and the skin are in close apposition, thermal
energy damage can extend to the germinative layer
of the epidermis, causing inside-out, full-thickness
necrosis, as occurred in three patients in the study.
Subcutaneous saline solution readily insinuates itself
between a superficial vein and the skin, as we docu-
Fig 9. Closure catheter positioning near saphenofemoral junction (SFJ). A, Compression wrap around
thigh and electrodes expanded just below superficial epigastric vein (SE) orifice. B, Treatment in progress
(wrap omitted to show undistorted treatment anatomy). C and D, Comparable views show catheter posi-
tioned as close to SFJ as possible; in D, note cul-de-sac (arrow) and lack of superficial epigastric vein
washout.
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mented several times with duplex scanning imaging
when tumescent anesthesia was used; this provides
both physical separation and a heat sink. Con-
sequently, Closure treatment should always be pre-
ceded by duplex scanning imaging of the entire
length of vein targeted for treatment. If segments
are identified that are within 5 mm of the underside
of the dermis, these should be treated by another
means or Closure-treated only after saline or saline-
anesthetic infiltration to separate vein and dermis,
preferably with duplex scanning confirmation.
The second procedure modification is used
ordinarily to reserve Closure treatment for refluxing
thigh veins to avoid thermally induced saphenous
and sural nerve trunk paresthesias. The incidence
and persistence of paresthesia and the degree to
which it bothers patients after surgical stripping are
commonly underestimated. When subjected to the
same scrutiny that characterized our study, Holme et
al’s17 prospective, randomized study of saphenous
nerve injury showed that the paresthesia incidence at
3 months was 39% when saphenectomy involved the
entire long saphenous vein and was significantly
reduced to 6% when stripping was limited to the
thigh and 4 cm below the knee. These differential
hazards reflect the relevant anatomy and apply
equally to Closure treatment. Sensory nerve injuries
in the thigh are to branches of the anterior and
medial femoral cutaneous nerves. Paresthesias from
injuries to these nerve branches resolve earlier than
those involving the saphenous or sural nerves
because of collateral branch reinnervation. The
saphenous nerve in the thigh is deep to the muscle
fascia, adjacent to the superficial femoral artery, and
it only emerges below the knee. Its main trunk
approaches apposition to the long saphenous vein at
a median of 15 cm below the popliteal crease,18 and
the sural nerve becomes close to the short saphe-
nous vein shortly after they perforate from the fascia,
making thermal or praxis injury more likely when
Closure treatment or stripping are continued into
the distal portion of the leg.
The third procedure modification is directed at
avoiding thrombus extension and embolism. Three
Closure patients had saphenous vein thrombi prop-
agate into the common femoral vein. The extensions
were free-floating, attached only at their base in the
saphenous orifice, and readily detectable by duplex
scanning. Two were clinically silent and identified
because the investigators advocated routine scan-
ning within 3 to 5 days of treatments performed
without flush high ligation. Both receded complete-
ly with low-molecular-weight heparin therapy. The
combination of being very detectable, very treatable,
and potentially very threatening argues strongly for
routine earlier surveillance.
Two of the three thrombus extensions involved
some uncertainty about catheter placement with
respect to the junction; one of these was in the patient
with an aggravating circumstance and pulmonary
emboli. Ideally, the catheter should be positioned to
begin obliteration just distal to the entrance of a
patent junctional tributary, as illustrated in Fig 9, A.
Starting treatment here ensures continual washing
over the orifice of the contracted saphenous vein, as in
Fig 9, B. Advancing the catheter beyond the entrance
of the tributaries, to the position shown in Fig 9, C,
eliminates smooth flow over the saphenous vein ori-
fice and creates a potential cul-de-sac, as illustrated in
Fig 9, D. Moreover, because the tributary vein is con-
tracted only for a short distance, as shown in Fig 9,
treating over a tributary’s orifice probably does not
result in its permanent occlusion. Accordingly, the
third procedure modification mandates that Closure
treatments without flush high ligation should begin
immediately distal to the orifice of a patent junctional
tributary and should be followed by duplex scanning
imaging of the saphenofemoral junction and confir-
mation of compliance with prescribed physical activi-
ties within 72 hours of treatment.
The fourth procedure modification is to make
the catheter pullback rate as regular as possible and
limit it to 3 cm/min or less everywhere along the
treatment course; this is because faster pullback rates
were associated with early patency. Early treatment
failures with persistent flow in the first week or flow
recurrence within the next 5 weeks had identical
mean pullback rates of 5.4 ± 3.1 cm/min; this was
Fig 10. Acute reduction (%) in valve diameters and
catheter dwell times associated with vein patency and early
thrombosis after Restore treatment.
significantly more rapid than the 3.3 ± 1.6 cm/min
rate used in treating still-closed veins (P < .001).
Closure catheters induce a 6- to 8-mm ring of con-
trolled vein wall heating, equating to a 12- to 16-sec-
ond exposure to 85°C when the catheter is with-
drawn at a steady 3 cm/min. Briefer exposure can
result in endothelial destruction with incomplete wall
contraction, usually causing thrombosis but not nec-
essarily achieving vein obliteration. Recanalization
beyond 6 weeks was associated with variable treat-
ment rates ranging from 1.9 to 6.0 cm/min.
Restore treatment
The Restore procedure has no electrosurgical
precedent, but the association of reflux with vein dila-
tion and its mitigation by diameter reduction are well
established.19-23 Vein diameter reduction is actually an
intended or incidental component of all treatments of
venous reflux disease short of extirpation, from com-
pressive wrapping and hosiery to deep-vein valvulo-
plasties, compression sclerotherapy included.19,20,22-27
The midterm results after Restore treatment were
better than could be accounted for by reducing
reflux to less than 1 second, which was true for only
seven patients (23%) at 6 months. CEAP clinical class
was significantly improved out to 1 year, and 45% of
the 31 patients followed up for 6 months or more
were free of all venous disease–related symptoms.
However, they were not necessarily reflux free (Fig
8), despite the significant reflux reduction through 1
year, as shown in Fig 5. A recent large study showed
that 17.7% of Edinburghers without known venous
disease had reflux for more than 1 second in at least
one vein segment, suggesting that symptom-free
reflux of this duration might be fairly common.28
The corollary to this observation might be that
decreasing reflux from 8 to 10 seconds to something
in the order of 2 seconds, as was true for 10 of the 14
asymptomatic patients, is clinically beneficial.
Occlusive thrombosis. The Restore treatment’s
most problematic aspects were a 16% incidence of
early occlusive thrombosis and later valve diameter
reexpansion. One thrombus extended into the com-
mon femoral vein, prompting a thrombectomy and
saphenectomy; the others left the patients with either
occluded or recanalized, refluxing, saphenous veins,
which effectively nullified the vein-saving advantage
of the Restore treatment. As shown in Fig 10, nine of
11 thromboses were associated with 30% or greater
diameter reduction and with catheters being in place
for 60 minutes or more. Catheter times shortened
with experience, but 37% mean shrinkage was need-
ed to attempt to reach a target diameter, which was
actually achieved in just 81% of patients. Mandating
less shrinkage might have avoided some thromboses
but would have had an adverse impact on the proce-
dure’s already marginal 60% efficacy in acutely reduc-
ing reflux to less than 1 second.
Valve diameter reexpansion. Valve diameter
reexpansion occurred principally during the first 6
weeks after treatment (Fig 5); this was due to dena-
tured collagen’s limited tensile strength.10,11 This
temporary decrease in tensile strength is unavoidable
and requires protection from tensile stress through
the healing phase to retain the clinical benefits of
shrinking. Effective compression of the saphenous
vein near the groin would have required custom-
made compressive leotards, which when new can
reduce the saphenous diameter by as much as 75% in
the standing position without any real reduction in
deep-vein diameter. Wearing them effectively during
the 6 weeks for which they appear to have been need-
ed would have tested the compliance motivation in
most patients and required the purchase of two or
three pairs of custom-made leotards at approximate-
ly $135 (US) each. We elected to forgo this inconve-
nience and expense for patients, asking them instead
to do things that would favor deep-vein flow and
thereby perhaps lessen tensile stress in the saphenous
vein. Leotard-wearing might have tempered valve
reexpansion, but it would not have improved the
60% expectation of acutely normalizing or eliminat-
ing reflux. Despite the inherent attractiveness of
functional vein restoration over obliteration or
removal, the Restore procedure, as studied in the
superficial venous system, is too limited in applicabil-
ity (mobile-but-not-meeting leaflets and a demon-
strable competence diameter) and too uncertain in its
effectiveness to compete with existing therapies. 
CONCLUSION
Innovative treatments need to be judged in the
context of time-tested existing therapies. For endove-
nous management of saphenous vein reflux, these are
high ligation and stripping, followed in order of
apparent effectiveness by (1) high ligation, either
alone or with sclerotherapy, and (2) sclerotherapy by
itself. Sarin et al29 observed an 18% rate of recurrent
reflux after high ligation and stripping and a signifi-
cantly higher reflux recurrence rate (45%) after high
ligation alone as early as 3 months after treatment.
Five-year studies, exemplified by a recent publication
of Dwerryhouse et al,30 indicate that reflux will even-
tually recur after stripping and high ligation in 29% of
patients—a smaller fraction (21%) developing recur-
rent varicosities—but that high ligation alone may
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have an eventual recurrent reflux rate as high as 71%.
When subjected to randomized study, high ligation
and sclerotherapy together were associated with a
reflux recurrence rate three times that observed after
high ligation and stripping at 3 years.31 Duplex scan-
ning after above-knee saphenous vein compression
sclerotherapy without high ligation showed a 75%
prevalence of recurrent or persistent reflux at a mean
of 27 months after treatment.32 Intraprocedural
duplex scanning guidance may have reduced reflux
recurrence to a rate as low as 26% at 1 year in a two-
practitioner personal series, which was hampered by
the fact that they had follow-up on only one third of
their patients.25
Closure treatment by itself should not be mis-
construed as an analog of high ligation without
saphenous stripping. In fact, the situation is exactly
the opposite; this is because high ligation interrupts
all saphenofemoral junction tributaries, potentially
stimulating neovascularity,33,34 and by design leaves
most of the saphenous vein patent. Ten percent of
successful Closure treatments (3 of 56 with high li-
gation and 11 of 86 without ligation) recanalized at
least some portion of a previously closed vein, but
with duplex-defined reverse flow in only 8 veins.
Closure treatment, therefore, at a mean follow-up of
4.7 months, has a 6% recurrent reflux rate and a 4%
(6 of 142 [four with high ligation]) incidence of
recurrent varicosities, indicating an early course sim-
ilar to that of saphenectomy. Restore treatment, on
the other hand, with recurrent or persistent reflux of
1 second or more in 25 (81%) of 31 patients followed
up for 6 to 12 months, reaches well into the realm of
sclerotherapy treatment alone without intraproce-
dural duplex scanning guidance. On the basis of this
initial experience, we propose that Closure treatment
is an effective, less invasive surrogate for saphenous
stripping, with notable complications and early fail-
ures that should largely be amenable to four proce-
dural modifications; in contrast, Restore valve shrink-
ing is simply too problematic to be competitive with
Closure treatment or saphenectomy.
We gratefully acknowledge the statistical advice and
analyses of Steven S. Lewis, PhD, of the Medical Data
Coordinating Center.
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